December 4-5 2023

2023 Biomarkers of Aging Symposium

The Premier Conference on Biomarkers of Aging for Longer and Healthier Lifespan

The Biomarkers of Aging Consortium is bringing together academic and industry leaders to share and discuss the latest advancements in biomarker development for predicting, improving and extending human lifespan.

Join our full-day, in-person event on December 4th 2023 at the scenic Buck Institute in Novato, California to help provide solid ground for our collective longevity R&D efforts. Our event will include a keynote lecture, short talks, panel discussions, as well as poster presentations from leading academic and industry scientists.

Key themes of the symposium:

  1. Conceptual frameworks and theories of aging and biomarkers of aging
  2. Assessment and validation of biomarkers of aging
  3. Application of biomarkers of aging for identification and evaluation of longevity interventions
  4. Challenges and opportunities for establishing reliable biomarkers of aging

Join Us To Make History

After years of community effort, anti-aging treatments will finally be coming to market in the near future. Yet we still lack standardized, clinically-validated tools to measure the aging process and quantitatively assess the impact of healthspan-extending interventions in humans. As our industry grows, standards are of paramount import.

Our dynamic, full-day symposium will be uniquely focused on sharing the latest research on biomarkers of aging, discussing the key issues we face in moving forward as a field, and defining priorities of the Consortium for the upcoming year.

Confirmed Participants (Speakers, Panelists, & Moderators) (A-Z)

Check out our world-class roster of pioneers. Updated on May 4th 2023.

  • Nir Barzilai, MD

    Nir Barzilai, MD

    Director of The Einstein Institute for Aging Research, Albert Einstein College of Medicine

    Dr. Barzilai is a Chaired Professor of Medicine and Genetics as well as the Director of The Einstein Institute for Aging Research, the largest center in the world to study the Biology of Aging. He leads the TAME (Targeting/Taming Aging with Metformin) multi-central study to prove the concept that multi-morbidities of aging can be delayed in humans and to change the FDA indications to allow for next generation interventions.

  • Daniel Belsky, PhD

    Daniel Belsky, PhD

    Assistant Professor of Epidemiology, Columbia University Mailman School of Public Health and Butler Columbia Aging Center

    Dr. Belsky's work focuses on reducing social inequalities in aging outcomes in the US and beyond. His research seeks to understand how genes and environments combine to shape health across the life course. His aim is to identify targets for policy and clinical interventions to promote positive development in early life and extend healthspan.

  • Brian Chen, PhD, MPH

    Brian Chen, PhD, MPH

    Chief Scientific Officer, FOXO Technologies

    Dr. Chen is the Chief Science Officer at FOXO Technologies, specializing in epigenetic technology for assessing human health and aging. He combines his expertise in epidemiology, bioinformatics, and machine learning to discover and validate biomarkers, publishing extensively on aging rates, genetic analysis, and epigenetic clock studies.

  • Alan	Cohen, PhD

    Alan Cohen, PhD

    Founder and CEO, Oken Health & Associate Professor, Columbia University

    Dr. Cohen, an Associate Professor at Columbia University, specializes in elucidating integrative biological processes and identifying reliable biomarkers of aging, health, and system integrity. Through the analysis of epidemiological data, his research contributes to a deeper understanding of health, aging, and longevity at multiple levels.

  • Alexander (Zan) Fleming, MD

    Alexander (Zan) Fleming, MD

    Co-Founder and Executive Chairman, Kinexum

    Dr. Fleming, the founder of Kinexum and a prominent figure in endocrinology, coined the term Metabesity to encompass the metabolic commonalities among cancer, chronic diseases, and aging. With notable achievements at the FDA and extensive involvement in biomarker initiatives and regulatory discussions, he is dedicated to advancing healthspan products and promoting healthy aging through conferences like the Targeting Healthy Longevity Conference.

  • Luigi Ferrucci, MD, PhD

    Luigi Ferrucci, MD, PhD

    Chief of the Longitudinal Studies Section, National Institute of Aging

    Dr. Ferrucci, the Scientific Director of the National Institute on Aging (NIA), conducts research on the pathways of physical and cognitive decline in older individuals, with a focus on inflammation, oxidative stress, and molecular damage. His influential work has led to notable progress in preventing and treating age-related diseases, such as cardiovascular disease, cancer, type 2 diabetes, and dementia.

  • Kristen Fortney, PhD

    Kristen Fortney, PhD

    CEO and Co-founder, BioAge

    Dr. Fortney is developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. Her company, BioAge, uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging. By targeting these pathways with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent these diseases in entirely new ways.

  • David Furman, PhD

    David Furman, PhD

    Associate Professor & Director, Buck Institute & Stanford 1,000 Immunomes

    Dr. Furman, an academic and entrepreneur, specializes in advanced statistics, AI, and machine learning for translational medicine. As the Director of the Stanford 1,000 Immunomes Project and an Associate Professor at the Buck Institute for Research on Aging, his research explores the immune system's involvement in aging and age-related diseases, with a particular focus on biomarkers of aging.

  • Vadim Gladyshev, PhD

    Vadim Gladyshev, PhD

    Professor of Medicine, Brigham and Women's Hospital

    Dr. Gladyshev, a renowned Professor of Medicine at Harvard Medical School and Director of the Center for Redox Medicine at Brigham and Women's, researches aging, lifespan control, and rejuvenation. His focus is on biomarkers of longevity and biological age, such as aging clocks, epigenetic signatures, and the human selenoproteome, revealing insights into aging mechanisms and the dynamic nature of biological aging under varying stress conditions.

  • Steve Horvath, PhD

    Steve Horvath, PhD

    Principal Investigator, Altos Labs

    Dr. Horvath, a renowned biogerontologist at Altos Labs, specializes in epigenetic biomarkers of aging. His pioneering work includes creating the first saliva epigenetic clock, the pan-tissue Horvath clock, and a universal clock for mammals. With numerous accolades and recognition, he is consistently ranked among the world's most influential scientific researchers.

  • Jamie Justice, PhD

    Jamie Justice, PhD

    Assistant Professor, Department of Internal Medicine Section on Gerontology and Geriatrics, Wake Forest School of Medicine

    Dr. Justice's research training spans various disciplines, species, and intervention strategies. Her current research includes the both the clinical trial Targeting Aging with MEtformin (TAME), which is designed to facilitate regulatory approval for metformin in order to slow biological aging, as well as investigating the therapeutic potential of targeting the biologic aging hallmark of cellular senescence in humans.

  • Andrea Maier, PhD, MD

    Andrea Maier, PhD, MD

    Oon Chiew Seng Professor in Medicine and Healthy Aging, Director Centre for Healthy Longevity at the National University of Singapore, Board Member the Longevity Science Foundation

    Dr. Maier focuses on sarcopenia and cellular senescence and their influence on age-related diseases. She serves as a Professor of Gerontology at VU University Amsterdam, The Netherlands, a President of the Australian and New Zealand Society for Sarcopenia and Frailty Research and as an Honorary Professor of Medicine and Aged Care at the University of Melbourne, Australia. She is also an Associate Editor of numerous international journals, such as Frontiers, the Gerontological Society of America, and is on the Editorial Board of ICT&Health.

  • Joan Mannick, MD

    Joan Mannick, MD

    CEO, Tornado Therapeutics

    Dr. Joan Mannick is the Chief Executive Officer of Tornado Therapeutics and develops safer and more effective mTOR inhibitors to treat or prevent disease. Dr. Mannick has extensive academic (Harvard Medical School, University of Massachusetts Medical School) and industry expertise (Novartis, Genzyme, resTORbio, Life Biosciences) in multiple therapeutic areas including aging biology.

  • Mahdi Moqri, PhD MBA

    Mahdi Moqri, PhD MBA

    Harvard & Stanford, The Biomakers of Aging Consortium

    Dr. Moqri, a joint Research Fellow at Harvard University’s Gladyshev Lab and Stanford University’s Snyder Lab, specializes in researching epigenetic and multi-omics biomarkers of aging. Additionally, he plays a key role in leading the Executive Committee of the Biomarkers of Aging Consortium, dedicated to establishing robust biomarkers for longevity interventions.

  • Birgit Schilling, PhD

    Birgit Schilling, PhD

    Director of Mass Spectrometry Core, Buck Institute for Research Aging

    Dr. Schilling, a Professor at the Buck Institute for Research on Aging and Director of the Mass Spectrometry Core, specializes in biomarkers of aging through proteome analysis. Her research examines protein modifications and their relevance to aging and age-related diseases, employing advanced analytical technologies to gain insights into fundamental aging biology and translational research.

  • Vittorio Sebastiano, PhD

    Vittorio Sebastiano, PhD

    Associate Professor, Obstetrics and Gynecology, Stanford University / Co-Founder, Turn Biotechnologies

    Dr. Sebastiano, an Associate Professor at Stanford University, pioneers cellular reprogramming to reverse aging in human cells and tissues. His research explores leveraging reproduction and embryonic development principles for anti-aging technologies, while leading research at Turn Biotechnologies for age-related disease therapies through transient cell reprogramming.

  • Michael Snyder, PhD

    Michael Snyder, PhD

    Principal Investigator, Synder Lab, Stanford University School of Medicine

    Dr. Snyder, the Stanford B. Ascherman Professor and Chair of Genetics at Stanford University, is a renowned leader in functional genomics and proteomics. His lab pioneers integrative personal omics profiling (iPOP) using cutting-edge technologies to assess disease risk and monitor personalized medicine. Additionally, Dr. Snyder has founded multiple companies, authored a book on genomics and personalized medicine, and serves on several company boards.

  • Eric Verdin, MD

    Eric Verdin, MD

    President & CEO, Buck Institute for Research Aging

    The Verdin Lab at the Buck Institute studies the relationship between aging and the immune system as well as how immune aging is regulated by nutrition. His lab has demonstrated how changes in the relative abundance of key cellular metabolites such as NAD+, acetylcoenzyme A, and the ketone body beta-hydroxybutyrate fluctuate under different nutritional conditions, including obesity, calorie restriction, fasting, time-restricted feeding, ketogenic diet, and how this influences immune responses. He is working on key enzymes regulated by these metabolites, which include sirtuins (NAD+), histone acetyltransferases (acetylcoenzyme A), and histone deacetylases (HDACs).

  • Alex Zhavoronkov, PhD

    Alex Zhavoronkov, PhD

    Founder & CEO, InSilico Medicine

    Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine, leads the company in pioneering next-generation generative AI technologies for drug discovery and biomarker development. With substantial funding, global expansion, and numerous partnerships, Insilico has made significant progress, advancing 11 preclinical candidates and entering human clinical trials with AI-discovered targets and designed molecules.

Thanks to our Sponsors

  • Buck Institute for Research on Aging
  • Hevolution Foundation Scientific Conferences Fund
  • Methuselah Foundation
  • VoLo Foundation

Your 2023 Symposium Chairs (A-Z)

  • Vadim Gladyshev, PhD

    Vadim Gladyshev, PhD

    Professor of Medicine, Brigham and Women's Hospital

  • Andrea Maier, MD

    Andrea Maier, MD

    Director Centre for Healthy Longevity at the National University of Singapore

  • Vittorio Sebastiano, PhD

    Vittorio Sebastiano, PhD

    Associate Professor, Obstetrics and Gynecology, Stanford University / Co-Founder, Turn Biotechnologies

  • Michael Snyder, PhD

    Michael Snyder, PhD

    Principal Investigator, Synder Lab, Stanford University School of Medicine

  • Eric Verdin, MD

    Eric Verdin, MD

    President & CEO, Buck Institute for Research Aging

Your 2023 Organizing Committee (A-Z)

  • Allison Duettmann

    Allison Duettmann

    President & CEO, Foresight Institute

  • Nicholas C. Fiorenza

    Nicholas C. Fiorenza

    Operations & Project Management, Methuselah Foundation

  • Dane Gobel

    Dane Gobel

    Co-Founder and Program Director, Methuselah Foundation

  • Chiara Herzog, PhD

    Chiara Herzog, PhD

    Postdoctoral Researcher, Universität Innsbruck

  • Mahdi Moqri, PhD, MBA

    Mahdi Moqri, PhD, MBA

    Research Fellow, Aging Research at Stanford School of Medicine & Visiting Scholar, Harvard Medical School.

  • Jesse Poganik, PhD

    Jesse Poganik, PhD

    Research Fellow, Brigham and Women's Hospital and Harvard Medical School

Your 2023 Volunteers (A-Z)

  • Ludger Goeminne, PhD

    Ludger Goeminne, PhD

    Postdoctoral Researcher, Harvard Medical School & Brigham and Women's Hospital

  • Alan Tomusiak

    Alan Tomusiak

    PhD Student, Buck Institute

  • Kejun (Albert) Ying

    Kejun (Albert) Ying

    PhD Student, Harvard University

About the Biomarkers of Aging Consortium

In late 2022, leaders in longevity science were brought together to empower geroscience research. Our growing Consortium comprises academic and industry scientists, clinicians, and regulatory experts working to bring biomarkers of aging to the clinic.

This synergistic combination of expertise is allowing us to take the steps required to establish common ground for our future work, and to realize the great potential of longevity research to improve human lives.

Visit our website to learn more about us and our work:

Follow us

Stay informed about the latest research on aging biomarkers and receive updates on the Consortium & Symposium.

  • Follow us on Twitter
  • Follow us on LinkedIn


The Buck Institute

8001, Redwood Boulevard Novato, CA United States, 94945

Registration period

March 17, 2023 - 17:23 until December 5, 2023 - 04:00

Contact us

For any questions about the event, please contact

Powered by Fourwaves